Enteric diseases are the infections caused by ingestion of contaminated food or water. These infections are commonly caused by bacteria and viruses. Poor maintenance of hygiene and sanitation, particularly due to rising population and urbanization is increasing the prevalence of enteric diseases. According to World Health Organization (WHO), around 2.2 million people are killed annually due to food and water-borne diarrheal diseases. There is an impending global demand for better diagnostic and therapeutic options to prevent the deaths from enteric diseases.
Portland, OR -- (SBWIRE) -- 09/07/2017 -- The factors influencing the growth of Enteric Disease Testing and Therapeutic Market are higher incidence of infectious diseases, overcrowded human population, poverty and lack of education about health and safety standards, unavailability of safe drinking water in many parts of the world and increasing microbial resistance to antibiotics. Moreover, according to WHO estimate, unfavorable changes in world climatic conditions such as rising global temperature and deforestation, would further increase the incidence of infectious diseases. However, inaccessibility to modern diagnostic and therapeutic options, high cost of equipment and lack of expertise are likely to restrict the growth of the market.
The global enteric disease testing and therapeutic market is segmented on the basis of disease, diagnostics, therapeutics and geography. According to disease, the market is segmented into bacterial disease such as typhoid, cholera, shigellosis, salmonellosis, clostridium difficile infections and campylobacteriosis; viral diseases such as rotavirus and novovirus infections; and parasitic diseases such as amoebiasis and giardiasis. Diagnostics market is segmented into diagnostic assays and rapid tests, testing of stool specimens, Complete Blood Count (CBC) test, blood culture test, urine test, antibody test and bone marrow test. Based on therapeutics, the global market is segmented into vaccines, antibiotics, Oral Rehydration Therapy (ORT) and others such as vitamins and zinc supplements. Geographically, the market is segmented across four regions viz., North America, Europe, Asia-Pacific and LAMEA.
Few of the strategies adopted by the key industry players are new product approval and acquisition. For instance, in May 2014, BD Diagnostics got FDA approval for BD MAX Enteric Bacterial Panel, an in vitro diagnostic test intended for the diagnosis of bacterial gastroenteritis. Similarly, Nanosphere Inc., got FDA approval for Verigene Enteric Pathogens Nucleic Acid Test (EP), a rapid diagnostic test for gastroenteritis. In July 2014, PaxVax acquired marketing, sales and distribution rights of Vivotif, an oral typhoid vaccine from Crucell Switzerland AG. The companies profiled in this report include Alere, Inc., GlaxoSmithKline plc, Becton Dickinson and Company, bioMérieux SA, Sanofi S.A., Bayer Pharma AG, Bio-Rad Laboratories, Inc., Quest Diagnostics Inc., and Trinity Biotech plc.
KEY MARKET SEGMENTS:
The global enteric disease testing and therapeutic market is segmented as below:
Global Enteric Disease Testing and Therapeutic Market ? By Disease
- Clostridium difficile infections
- Rotavirus infections
- Novovirus infections
Get PDF Brochure of this report Study: https://www.alliedmarketresearch.com/request-toc-and-sample/655
Early buyers will receive 20% customization on this report